Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

MDGL

Live52w high -15.1%

Annual Quarterly

Core line items from MDGL's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Entity: MADRIGAL PHARMACEUTICALS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$358.36M	$311.34M	$958.40M	$637.32M	$350.05M
Operating Income	Not available	$-92.72M	$-300.10M	$-240.49M	$-126.51M
Net Income	Not available	$-94.39M	$-288.28M	$-229.71M	$-42.28M
EPS (Diluted)	$-2.09	$-3.25	$-10.15	$-8.12	$-4.10
Total Assets	Not available	$1.23B	$1.26B	$1.36B	$1.02B
Total Liabilities	Not available	$683.87M	$656.90M	$736.73M	$319.40M
Cash & Equivalents	Not available	$227.03M	$198.69M	$295.69M	$186.19M
Free Cash Flow OCF − CapEx	Not available	$-171.28M	$-190.02M	$-56.95M	$-135.94M
Shares Outstanding	Not available	23.04M	22.84M	22.70M	22.22M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from MDGL's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -15.1%

Entity: MADRIGAL PHARMACEUTICALS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$358.36M	$311.34M	$958.40M	$637.32M	$350.05M
Operating Income	Not available	$-92.72M	$-300.10M	$-240.49M	$-126.51M
Net Income	Not available	$-94.39M	$-288.28M	$-229.71M	$-42.28M
EPS (Diluted)	$-2.09	$-3.25	$-10.15	$-8.12	$-4.10
Total Assets	Not available	$1.23B	$1.26B	$1.36B	$1.02B
Total Liabilities	Not available	$683.87M	$656.90M	$736.73M	$319.40M
Cash & Equivalents	Not available	$227.03M	$198.69M	$295.69M	$186.19M
Free Cash Flow OCF − CapEx	Not available	$-171.28M	$-190.02M	$-56.95M	$-135.94M
Shares Outstanding	Not available	23.04M	22.84M	22.70M	22.22M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.